



Brigid Sharek

Associate

brigid.sharek@icemiller.com

614 462 2256

In her practice, Brigid Sharek focuses on a range of matters that include life sciences agreements and technology transactions, acquisitions, asset purchases, licenses, research and development partnerships, joint ventures, manufacturing and supply agreements, and confidentiality matters. She also advises clients on the application of privacy laws, including HIPAA and GDPR compliance.

As an associate in Ice Miller's Business Group, Brigid works closely with clients to provide strategic, effective, and experienced legal counsel to achieve their business goals.

Prior to her career in law, Brigid completed post-graduate work in the field of biochemistry and conducted research in neurobiology.

Education

- Texas A&M University-Corpus Christi (B.S., *summa cum laude*)
 - Chemistry
- University of Notre Dame (M.S., 2010)
 - Biochemistry
- The Ohio State University Moritz College of Law (J.D., 2018)

Admissions

- Illinois
- North Carolina
- Ohio
- United States Patent and Trademark Office

Community Involvement

- Science Fair Judge, State Science Day; Buckeye Science and Engineering Fair

Services & Industries

- Business
- Intellectual Property
- Licensing
- Life Sciences & Biotechnology
- Mergers & Acquisitions
- Patents
- Software, eCommerce & Technology Transactions
- Supply Chain & Logistics

Success Stories

Ice Miller Helps Client Secure a Strategic Collaboration with Johnson & Johnson

Ice Miller's South Korea-based client Prazer Therapeutics Inc. (Prazer) has entered into a strategic collaboration and license agreement with Johnson & Johnson (J&J) to advance the discovery of novel therapeutics for neurodegenerative diseases. This partnership follows Prazer's Series B financing led earlier this year by J&J, through its corporate venture capital organization, Johnson & Johnson Innovation (JJDC, Inc.).

Prazer is a biotechnology company developing orally available, brain-penetrant targeted protein degraders with a novel approach to targeted protein degradation (TPD). Their proprietary SPiDEM™ platform is engineered to identify new degradation mechanisms and address limitations associated with traditional bivalent and monovalent protein degraders. This new collaboration with J&J will help Prazer leverage their innovation platform and advance targeted protein degradation to accelerate the discovery of new potential TPD medicines for patients.

The Ice Miller deal team was led by Business group partner TaeSoo Sean Kim and included partner Mai Zymaris and law clerk Kelly Xia (not yet admitted to practice in any jurisdiction). Intellectual Property partners Fabian Koenigbauer and Robert Keeler also provided key assistance. Further assistance was provided by associate Brigid Sharek.

Ice Miller's Life Sciences practice group has extensive experience working with biotechnology companies to help them with seed-stage funding, intellectual property procurement and counseling, and licensing and strategic alliances.

Ice Miller Represents Forge Biologics in \$620M Acquisition by Ajinomoto

Forge Biologics Holdings, LLC, a Columbus, Ohio-based premier gene therapy contract development & manufacturing organization, has been acquired by the Ajinomoto Group, a Japanese multinational food and biotechnology public company, in an all-cash \$620M deal.

The Ice Miller deal team was led by Edward Braum and Dann Bruno, with additional corporate support from Erik Olson, Kevin Burns, Ben Goodman, Chris Michael, Chelsea Abramowitz, Brigid Sharek, Huidi Shu, and Lisa Samblanet. Kathleen Scheidt, Dan Corsaro, Nick Casto, Sean Kim, Holly Banta, Cathy Strauss, Anthony Aaron, Grace Dahm, Nick Reuhs, and Brian Harvey provided specialist support.

Ice Miller has represented Forge since its inception in 2020 through its various rounds of venture capital financing, including its \$40M Series A financing in 2020, \$120M Series B financing in 2021, and \$90M Series C financing in 2022. Ice Miller Business Group partners Edward Braum and Sean Kim have represented Forge through its growth, with Ed overseeing the structuring and financing of the company, and Sean facilitating licensing and day-to-day commercial transactions.

This representation further highlights Ice Miller's rapidly growing life sciences practice, with the acquisition placing Forge in a position for long-term growth. The transaction also supports Ajinomoto's desire to extend its development and manufacturing of gene therapies worldwide.